Liberum has updated its target price for Futura Medical PLC (AIM:FUM, OTC:FAMDF) shares from 121p to 142p after the latter's announcement of US Food & Drug Administration approval for MED3000, a treatment for erectile dysfunction (ED), according to the corporate broker's research note.
This development marks a significant milestone for Futura, further strengthening the investment case in the Liberum's view.
Atossa Therapeutics Inc (NASDAQ:ATOS), which is developing medicines aimed at oncology and breast cancer, revealed that the pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE study, evaluating Endoxifen versus exemestANe GosEreLIn, has now fully enrolled.
The Seattle-based clinical-stage biopharma’s EVANGELINE study is one of two ongoing Phase 2 trials investigating Atossa’s proprietary (Z)-endoxifen as a neoadjuvant treatment, for women with estrogen receptor positive breast cancer.
First Phosphate Corp. (CSE:PHOS) revealed that world-renowned battery technology expert Isobel Sheldon OBE, the founder and principal consultant of Oakpolytech Limited, had joined the company’s advisory board.
Having amassed nearly 20 years of lithium-ion battery industry experience and familiarity with the global battery landscape, Sheldon will guide First Phosphate, which is focused on extracting and refining advanced phosphate material from its Saguenay, Quebec-based assets for the LFP battery industry.
Standard Uranium Ltd (TSX-V:STND, OTCQB:STTDF) has announced a shift in its business model from exploration-only to a more expansive project generator model, aimed at increasing capital efficiency and accelerating the progress of its exploration projects.
The company said it plans to engage joint-venture partners for the development of its prospective land package while retaining upside exposure to any discoveries.
In a significant milestone for UK-based Futura Medical PLC (AIM:FUM, OTC:FAMDF) and a first for the US, the Food and Drug Administration (FDA) has approved the over-the-counter marketing of the company's innovative topical gel for erectile dysfunction (ED).
MED3000 can now be sold without prescription, paving the way for the topical ED treatment to become available on the shelves of American pharmacies.
Powertap Hydrogen Capital Corp has released the results of its annual general meeting held on June 8, 2023, where all matters submitted to shareholders for approval as set forth in the company's notice of meeting and information circular were approved. There were 15 shareholders represented in person or by proxy at the meeting, holding 2,855,601 common shares, representing 0.61% of the company's total issued and outstanding common shares as of the record date for the meeting.
ACME Lithium Inc has announced that the expiry dates of the share purchase warrants issued by the company on June 21, 2021 and July 2, 2021 have been extended for two years to June 21, 2025 and July 2, 2025 respectively. The warrants were originally issued as part of a unit private placement. Each $0.40 unit consisted of one common share and one-half of one share purchase warrant, with each whole warrant exercisable for a period of two years (expiring June 21, 2023 and July 2, 2023 respectively) at $0.60 per share. Of the original 4,512,084 warrants issued, there remain 3,686,459 warrants outstanding. There is no change to the exercise price.
Phunware Inc has said it will be attending and holding one-on-one meetings at the Cantor Fitzgerald Technology Conference on Wednesday, June 14, 2023 at the Ease Hospitality event venue in New York City, NY. For additional information or to schedule a one-on-one meeting with Phunware management, interested parties should contact Gateway Investor Relations at PHUN@Gateway-grp.com.
Kainantu Resources Ltd said it has extended the close of its previously announced private placement of senior convertible debentures to June 16, 2023. The debentures will have a conversion price of C$0.08 per common share provided that the company does not complete a consolidation of its outstanding common shares which would result in a conversion price of at least $0.10 on a post-consolidation basis. Closing of the private placement and the consolidation remain subject to approval from the TSX Venture Exchange.
Royal Helium Ltd said it has closed its previously announced ‘bought deal’ private placement financing of $7 million, which has been upsized to $7.3 million due to excess demand. Under the placement, Royal Helium issued 7,300 non-transferable unsecured convertible debenture units at $1,000 per unit, with each unit consisting of one 12% unsecured convertible debenture in the principal amount of $1,000 and 2,703 common share purchase warrants. President and CEO Andrew Davidson said the net proceeds of this raise are being used for ancillary midstream equipment and services related to the commissioning of the Steveville helium processing facility that are outside the scope of the project financing already in place for the facility. Proceeds will also allow the company to reinitiate exploration activities over other projects in Saskatchewan and Alberta, he added.
Burcon NutraScience Corporation said it will hold an investor conference call and webcast on Thursday, June 22, 2023, at 5pm Eastern Time to discuss its financial results for the fiscal year ended March 31, 2023. The webcast can be found at: https://viavid.webcasts.com/starthere.jsp?ei=1617306&tp_key=fd64bc62b6.